---
title: "3SBIO drops 5% as US plans curbs on China biotech investment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303156992.md"
description: "3SBIO fell 5.25% to HK$13.18 as a U.S. proposal to restrict biotech investment in China weighed on the sector."
datetime: "2026-10-27T02:54:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303156992.md)
  - [en](https://longbridge.com/en/news/303156992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303156992.md)
generator: "portal-rs"
---

# 3SBIO drops 5% as US plans curbs on China biotech investment

3SBIO (1530.HK) fell more than **5%** in Hong Kong trading to **HK$13.18**.

The U.S. Department of the Treasury released a draft of the Comprehensive Outbound Investment National Security Act, proposing restrictions on biotechnology investment in China. The proposal triggered a market reaction, weighing on shares of innovative drugmakers.

Although the policy has not yet been implemented and total outbound licensing deals for Chinese innovative drugs reached **$130 billion** in the first three quarters, industry participants are monitoring whether the measures could disrupt overseas expansion trends or affect equity investments and NewCo structures.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [SanRex proposes to acquire Frontage Holdings for HKD 2.370 per share](https://longbridge.com/en/news/304839252.md)
- [KNR Constructions' (NSE:KNRCON) Conservative Accounting Might Explain Soft Earnings](https://longbridge.com/en/news/306343335.md)
- [LIVESTOCK-Cattle futures rise ahead of bullish USDA feedlot data](https://longbridge.com/en/news/306343208.md)
- [Binance hack: $2.82 billion frozen, only $32 million recovered](https://longbridge.com/en/news/306342062.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**